CTXR Stock News & Catalysts – Citius Pharmaceuticals

FEATURED

Citius Oncology's Positive Quality of Life Data for LYMPHIR® (denileukin diftitox-cxdl) in Relapsed or Refractory Cutaneous T-Cell Lymphoma Presented at Premier Global CLTG Congress in Europe

Data featured in oral presentation at the European Organisation for Research and Treatment of Cancer Cutaneous Lymphoma Tumour Group (EORTC-CLTG) 2026 Annual Meeting in BerlinPatients who responded to LYMPHIR reported

Summary

Nov 4, 2026, 1:45 PM ·PRNewswire

RECENT

Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026

CRANFORD, N.J., Oct. 26, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (NASDAQ:CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of

Oct 26, 2026, 1:00 PM ·PRNewswire

Citius Pharmaceuticals to Participate in October 2026 Investor Conferences

Chairman and CEO Leonard Mazur to present and host one-on-one investor meetings at the 2026 Maxim Growth Summit and the ThinkEquity ConferenceCRANFORD, N.J., Oct. 12, 2026 /PRNewswire/ -- Citius Pharmaceuticals, Inc.

Oct 12, 2026, 8:30 AM ·PRNewswire

Citius Pharmaceuticals to Participate in September 2026 Investor Conferences

Chairman and CEO Leonard Mazur to present and host one-on-one investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference and Moody Capital Solutions 2026 Disruptive Growth & Life Sciences

Sep 3, 2026, 8:30 AM ·PRNewswire

Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

$7.1 million in revenue for the first nine months of fiscal 2026 as the LYMPHIR® launch progressesStrong institutional demand drives growth in total vials ordered and number of institutions orderingLYMPHIR ordered by 44

Aug 14, 2026, 4:30 PM ·PRNewswire

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

$7.1 Million in revenue for the first nine months of fiscal 2026 from commercial sales of LYMPHIR ®$17 million in cash and cash equivalents as of June 30, 2026Expanded LYMPHIR commercial and medical affairs

Aug 14, 2026, 4:30 PM ·PRNewswire

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri

CRANFORD, N.J., Aug. 12, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc.

Aug 12, 2026, 8:00 AM ·PRNewswire

Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment

New institutional accounts ordering LYMPHIR increased 78% quarter over quarterLYMPHIR's near-universal payer coverage expands market accessInitial cutaneous T-cell lymphoma (CTCL) market for LYMPHIR currently

Aug 5, 2026, 9:17 AM ·PRNewswire

Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption

Expanded commercial and medical affairs teams expected to be fully operational throughout the U.S. by August CRANFORD, N.J., July 21, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR),

Jul 21, 2026, 9:17 AM ·PRNewswire

Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies

Investigator-initiated study data presented May 30, 2026, at the American Society of Clinical Oncology (ASCO) Annual Meeting demonstrated durable responses and manageable tolerability in heavily pre-treated patients20.5

Jun 1, 2026, 7:00 AM ·PRNewswire

Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting

24% Objective Response Rate, with an average of 21.1 month Duration of Response in responders, and favorable safety profile signals potential of LYMPHIR to augment immune checkpoint inhibitor efficacy

May 26, 2026, 8:00 AM ·PRNewswire

Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update

$5.6 million in net revenue for the first half of fiscal 2026 as LYMPHIR® launch progressesUp to $36.5 million in debt and equity capital securedBroad payer coverage established with no reimbursement denials83% of

May 15, 2026, 4:30 PM ·PRNewswire

Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update

$5.6 Million in net revenue for the first half of fiscal 2026 from ongoing launch of LYMPHIR®Citius Pharma raised $5 million in a registered direct offering; Citius Oncology secured up to $36.5 million in debt and

May 15, 2026, 4:30 PM ·PRNewswire

Citius Oncology Ships First International Order of LYMPHIR™ to Europe

Order fulfilment expands international patient access to LYMPHIR following initial U.S. launchDistribution by regional partners through Named Patient Programs in specific international marketsCRANFORD, N.J., April 29,

Apr 29, 2026, 8:00 AM ·PRNewswire

Citius Pharmaceuticals Announces Closing of Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules

CRANFORD, N.J., April 24, 2026 /PRNewswire/ -- Citius Pharmaceuticals Inc. (NASDAQ:CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization

Apr 24, 2026, 4:30 PM ·PRNewswire

Citius Pharmaceuticals, Inc. CTXR · News